[Laboratory and clinical studies on cefpimizole in the field of gynecology].
Cefpimizole (AC-1370), a new cephalosporin antibiotic, was evaluated for its distribution in uterine tissue, penetration into retroperitoneal exudate and therapeutical effects on some infections in gynecology. The following results were obtained; The levels of AC-1370 in the cubital vein were similar to those in the uterine artery and this remained in the course of examinations after an 1 g intravenous injection. Seven patients with gynecological infections received AC-1370 by intravenous injection. The overall efficacy rate was 85.7%. No adverse reaction was observed in any of the cases treated with AC-1370, nor was there any marked changes in the laboratory findings.
D000328:Adult; D001424:Bacterial Infections / Q000188:drug therapy*; D002511:Cephalosporins / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use*; D004341:Drug Evaluation; D005122:Exudates and Transudates / Q000378:metabolism; D005260:Female; D005831:Genital Diseases, Female / Q000188:drug therapy*; D005836:Genitalia, Female / Q000378:metabolism; D006801:Humans; D007275:Injections, Intravenous; D008875:Middle Aged; D012187:Retroperitoneal Space
D002511:Cephalosporins; C038845:cefpimizole